Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Horizon Pharma's (HZNP) FY16 Revenue Guidance Tops Views
November 9, 2015 8:01 AM ESTHorizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, will host an investor meeting today where for the first time it is providing full-year 2016 net sales and adjusted EBITDA guidance and outlining its long-range plan for its current portfolio of medicines. The Company's presentation will begin... More
Mizuho Bullish on Horizon Pharma (HZNP) Into Today's Investor Day
November 9, 2015 6:51 AM ESTHorizon Pharma (NASDAQ: HZNP) is hosting its analyst day today at 11:30 and will offer short and long term guidance as it grows increasingly focused on its Orphan franchise. The analyst day will be key to drawing distinctions between Horizon's and Valeant's specialty pharma models. PBMs... More
Guggenheim Shows Increasing Confidence in Horizon Pharma (HZNP) Following 3Q Beat; Reiterates Buy
November 6, 2015 11:10 AM ESTGuggenheim reiterated a Buy rating and $40.00 price target on Horizon Pharma (NASDAQ: HZNP) following the company's 3Q15 earnings report. HZNP reported adjusted diluted 3Q15 EPS of $0.70, $0.29 above consensus. The company also raised its '15 EBITDA guidance to $350MM-$360MM from $265MM-$280MM, consensus was... More
